SOLENO THERAPEUTICS INC Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flows from operating activities:
Net income (loss)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization
Accretion of premium/discount on marketable securities
Non-cash lease expense
Amortization of debt issuance costs
Stock-based compensation expense
Change in fair value of stock warrants
Change in fair value of contingent consideration
Other non-cash reconciling items
Change in operating assets and liabilities:
Accounts receivable
Inventory
Prepaid expenses, other current assets and other assets
Accounts payable
Accrued compensation
Accrued clinical trial site costs
Operating lease liabilities
Other liabilities
Net cash provided by (used in) operating activities
Cash flows from investing activities:
Purchases of property and equipment
Purchases of marketable securities
Maturities of marketable securities
Net cash used in investing activities
Cash flows from financing activities:
Gross proceeds from sale of common stock and common stock warrants
Payment of issuance costs
Proceeds from issuance of debt, net of issuance costs
Payment of debt issuance costs
Proceeds from the sale of common stock, net of issuance costs
Proceeds from the sale of common stock, common stock warrants and pre-funded stock warrants, net of issuance costs
Payment for repurchase of common stock
Proceeds from exercise of common stock and pre-funded stock warrants
Proceeds from exercise of stock options
Tax withholding payments for net share-settled equity awards
Principal paid on finance lease liabilities
Net cash provided by financing activities

Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents, beginning of period
Cash and cash equivalents, end of period
Supplemental disclosure of non-cash operating and financing information
Operating lease right-of-use assets obtained in exchange for operating lease obligations
Cash paid for interest
Common stock repurchase costs included in accounts payable
Non-cash exercise of 2018 PIPE Warrants
Purchases of property and equipment included in accounts payable
Debt issuance costs included in accounts payable

Comments